Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

被引：13

作者：

Arias Ron, David ^{[1
]}

Labandeira, Carmen M. ^{[2
]}

Areses Manrique, Maria Carmen ^{[1
]}

Sampedro Domarco, Paula ^{[1
]}

Abdulkader, Ihab ^{[3
]}

Garcia-Mata, Jesus ^{[1
]}

Rolfo, Christian ^{[4
]}

Gonzalez-Rivas, Diego ^{[5
,6
]}

Luis Firvida, Jose ^{[1
]}

机构：

[1] Univ Hosp Complex Ourense, Med Oncol Dept, Orense, Spain

[2] Hosp Alvaro Cunqueiro, Neurol Dept, Univ Hosp Complex Vigo, Pontevedra, Spain

[3] Univ Hosp Complex Santiago de Compostela, Anatomopathol Dept, Santiago De Compostela, Spain

[4] Univ Maryland, Thorac Med Oncol, Early Clin Trials, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[5] Hosp San Rafael, Thorac Surg Dept, Coruna, Spain

[6] Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

squamous lung cancer; nivolumab; leptomeningeal carcinomatosis; PD-L1; complete response; BRAIN METASTASES; 1ST-LINE CHEMOTHERAPY; OPEN-LABEL; DOCETAXEL; NSCLC; VINORELBINE; ERLOTINIB; SURVIVAL; EFFICACY; OUTCOMES;

D O I：

10.3389/fonc.2019.00819

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumor growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects. High expression PD-L1 level (100%) was found in the pathological tissue sample. Nivolumab was maintained for more than 2 years and stopped in December 2017 after 28 months of treatment, with no disease evidence. More than 3 years after its onset, the patient maintains an outstanding PS with complete tumor response and no evidence of disease in last surveillance CT scan and brain MRI.

引用

页数：8

共 35 条

[1] PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data [J].

Aguiar, Pedro N., Jr. ;

De Mello, Ramon Andrade ;

Hall, Peter ;

Tadokoro, Hakaru ;

de Lima, Gilberto .

IMMUNOTHERAPY, 2017, 9 (06) :499-506

[2] Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases [J].

Ahmed, Kamran A. ;

Kim, Sungjune ;

Arrington, John ;

Naghavi, Arash O. ;

Dilling, Thomas J. ;

Creelan, Ben C. ;

Antonia, Scott J. ;

Caudell, Jimmy J. ;

Harrison, Louis B. ;

Sahebjam, Solmaz ;

Gray, Jhanelle E. ;

Etame, Arnold B. ;

Johnstone, Peter A. ;

Yu, Michael ;

Perez, Bradford A. .

JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (02) :331-338

[3] LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non-Small-Lung Cancer [J].

Arrondeau, Jennifer ;

Ammari, Samy ;

Besse, Benjamin ;

Soria, Jean-Charles .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (08) :E62-E63

[4] Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) [J].

Barlesi, F. ;

Gervais, R. ;

Lena, H. ;

Hureaux, J. ;

Berard, H. ;

Paillotin, D. ;

Bota, S. ;

Monnet, I. ;

Chajara, A. ;

Robinet, G. .

ANNALS OF ONCOLOGY, 2011, 22 (11) :2466-2470

[5]

Berghoff Anna S, 2016, Am Soc Clin Oncol Educ Book, V35, pe116, DOI 10.14694/EDBK_100005

[6] Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases [J].

Berghoff, Anna S. ;

Fuchs, Elisabeth ;

Ricken, Gerda ;

Mlecnik, Bernhard ;

Bindea, Gabriela ;

Spanberger, Thomas ;

Hackl, Monika ;

Widhalm, Georg ;

Dieckmann, Karin ;

Prayer, Daniela ;

Bilocq, Amelie ;

Heinzl, Harald ;

Zielinski, Christoph ;

Bartsch, Rupert ;

Birner, Peter ;

Galon, Jerome ;

Preusser, Matthias .

ONCOIMMUNOLOGY, 2016, 5 (01)

[7] Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC) [J].

Berghoff, Anna Sophie ;

Ricken, Gerda ;

Wilhelm, Dorothee ;

Rajky, Orsolya ;

Widhalm, Georg ;

Dieckmann, Karin ;

Birner, Peter ;

Bartsch, Rupert ;

Preusser, Matthias .

JOURNAL OF NEURO-ONCOLOGY, 2016, 130 (01) :19-29

[8] First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study [J].

Bernardo, G ;

Cuzzoni, Q ;

Strada, MR ;

Bernardo, A ;

Brunetti, G ;

Jedrychowska, I ;

Pozzi, U ;

Palumbo, R .

CANCER INVESTIGATION, 2002, 20 (03) :293-302

[9]

Bidoli P., 2016, Annals of Oncology, V27, P416, DOI [DOI 10.1093/ANNONC/MDW383.28, 10.1093/annonc/mdw383, DOI 10.1093/ANNONC/MDW383, DOI 10.1093/ANN0NC/MDW383.28]

[10] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

← 1 2 3 4 →